BRIEF published on 03/20/2025 at 07:05, 10 months 26 days ago Innate Pharma annonce une conférence sur les résultats financiers 2024 Résultats Financiers Conférence Téléphonique Cotation Boursière Innate Pharma Immunothérapie Cancer
BRIEF published on 03/20/2025 at 07:05, 10 months 26 days ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 10 months 26 days ago Informations privilégiées / Autres communiqués Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats financiers 2024. Détails de l'événement et informations pratiques disponibles sur www.innate-pharma.com Résultats Financiers Webcast Conférence Téléphonique Innate Pharma Biotechnologies
PRESS RELEASE published on 03/20/2025 at 07:00, 10 months 26 days ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 11 months 26 days ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 11 months 26 days ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 11 months 26 days ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 11 months 26 days ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
Published on 02/14/2026 at 01:00, 2 days 2 hours ago Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:15, 2 days 5 hours ago Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 2 days 9 hours ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 2 days 13 hours ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/15/2026 at 16:35, 11 hours 9 minutes ago Arab Palestinian Investment Company (APIC) achieves USD 8.13 million in net income attributable to shareholders and reports record sales of USD 1.31 billion in 2025
Published on 02/15/2026 at 11:43, 16 hours 1 minute ago EQS-Adhoc: The Management Board of Hapag-Lloyd Aktiengesellschaft confirms negotiations regarding an acquisition of Zim Integrated Shipping Services Ltd.
Published on 02/15/2026 at 11:05, 16 hours 39 minutes ago WePlay Debuts in German Market with "The Little Prince" Special Valentine's Day Collaboration
Published on 02/15/2026 at 09:35, 18 hours 9 minutes ago Canary Islands at the Berlinale European Film Market with more than 40 professionals from the islands
Published on 02/14/2026 at 16:30, 1 day 11 hours ago Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/13/2026 at 18:05, 2 days 9 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 2 days 9 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 2 days 9 hours ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 2 days 9 hours ago Nombre total d'actions et droits de vote - janvier 2026
